Skip to content
ATLAS PREP HQ
Healing

GHK-Cu

Glycyl-L-histidyl-L-lysine copper(II) complex; copper tripeptide-1

Copper-binding peptide research centered on collagen synthesis, skin quality, tissue remodeling, and wound repair.

Limited Human Evidence

Route

Topical is the route with the clearest cosmetic human data

Common format

50 mg vial

Research focus

skin aging

Evidence level

Limited Human Evidence

Typical cycle

8–12 weeks

Healing research motifHealing

GHK-Cu in 30 seconds

Atlas Fast Read

What it is

Glycyl-L-histidyl-L-lysine copper(II) complex; copper tripeptide-1

Why people care

Copper-binding peptide research centered on collagen synthesis, skin quality, tissue remodeling, and wound repair.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Topical and systemic evidence must be separated. Major gaps include injectable pharmacokinetics, long-term systemic copper handling, dose-response, and whether cosmetic/wound findings translate to systemic performance or recovery claims.

Bottom line

GHK-Cu is more credible than many recovery peptides when the claim stays close to topical skin and wound-remodeling data.

Overview

What is GHK-Cu?

GHK-Cu is glycyl-L-histidyl-L-lysine copper(II) complex; copper tripeptide-1. Copper-binding peptide research centered on collagen synthesis, skin quality, tissue remodeling, and wound repair.

GHK was identified in human plasma by Loren Pickart in the 1970s and later recognized as a high-affinity copper-binding tripeptide. Research expanded into wound healing, skin remodeling, hair biology, and gene-expression effects.

Mechanism

How it works

Binds and delivers copper to enzymes involved in collagen cross-linking and antioxidant defense, while also influencing growth factors, matrix metalloproteinases, inflammation, and broad gene-expression programs related to tissue remodeling.

Research areas

skin agingcollagen remodelingwound healinghair biology

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human evidence is strongest for topical/cosmetic uses, where small clinical studies and decades of dermatologic use support effects on skin appearance and wound-related biology. Evidence for systemic injectable GHK-Cu is much thinner and should not be inferred from topical data.

Preclinical evidence

Cell and animal studies support wound healing, collagen remodeling, angiogenesis, antioxidant activity, and broad gene-expression effects. This preclinical breadth complements, but exceeds, the scope of current human topical data.

Knowledge gaps

Topical and systemic evidence must be separated. Major gaps include injectable pharmacokinetics, long-term systemic copper handling, dose-response, and whether cosmetic/wound findings translate to systemic performance or recovery claims.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 1–2 mg/day SC with titration; topical GHK-Cu has a different evidence base and cannot be dose-converted from injectable protocols.

Frequency

Once daily, 5 days on / 2 days off in the community protocol.

Timing

Any consistent time; no validated timing advantage.

Route

Topical is the route with the clearest cosmetic human data; Community sources also list subcutaneous research use.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2.5 mL bacteriostatic water per 50 mg vial = 20 mg/mL.

Storage

Community reference: lyophilized at -20 °C; reconstituted 2–8 °C and use within 30 days.

Monitoring

For prolonged systemic copper-peptide research, consider CBC/CMP and copper/zinc status if clinically indicated; for topical use, monitor irritation and skin outcomes.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Topical GHK-Cu is generally associated with local irritation or dermatitis in susceptible users. Injectable/systemic adverse effects are not well characterized; theoretical concerns include altered copper balance and injection reactions.

Contraindications

No validated systemic contraindication profile exists. Copper-metabolism disorders, significant liver disease, pregnancy/breastfeeding, active malignancy or copper hypersensitivity warrant specialist review.

Interactions

Systemic interaction data are sparse. Zinc/copper supplementation can alter mineral balance; chelators can affect copper availability. Topical interactions are primarily formulation/irritation related.

Stacks

Common stacks

GHK-Cu + BPC-157

Discussed for matrix remodeling plus injury/gut repair research.

No controlled human evidence for the systemic combination; topical GHK-Cu evidence should be kept separate.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

GHK-Cu is more credible than many recovery peptides when the claim stays close to topical skin and wound-remodeling data. The evidence becomes much weaker when topical findings are repackaged as proof for systemic injections, whole-body regeneration, or longevity.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide